Evaluating an Innovative Tobacco Treatment Approach for Veterans in Substance Use Treatment (Co-STOP)
Evaluating an Innovative Tobacco Treatment Approach for Veterans in Substance Use Disorder Treatment
研究概览
地位
详细说明
This project will generate knowledge about strategies to increase smoking treatment engagement in Veterans with substance use disorders, a group that suffers disproportionately from smoking-related disease and death. This project will This project will evaluate the acceptability, feasibility, and preliminary efficacy of the Co-STOP program relative to standard cessation treatment offered at the VA. Co-STOP is an intervention designed to make tobacco treatment part of routine care for Veterans in substance use treatment and thereby enhance tobacco treatment use and quit attempts. Co-STOP offers evidence-based counseling and nicotine replacement therapy for smoking cessation as well as smoking reduction or changes if Veterans are not willing to quit. In Co-STOP, treatment is provided unless the Veteran declines, and makes tobacco treatment the default during substance use treatment. It is expected that Enhanced Chronic Care will increase treatment use and smoking abstinence relative to Standard Care.
This project will randomize N=112 Veterans receiving VA outpatient SUD care who smoke daily in a 1:1 ratio to Co-STOP or SC in a pilot randomized controlled trial (RCT). Co-STOP participants will be informed that they will be provided with evidence-based smoking treatment, which does not require a commitment to quit, as part of their SUD care, unless they opt-out. Co-STOP participants who do not opt out will receive 4 months of nicotine replacement therapy (NRT) and five behavioral counseling calls to support making 'healthy changes' or quitting smoking. SC participants will be offered entry into standard VA cessation treatment. Outcomes will be assessed over 4-months post-study entry. The investigators hypothesize that relative to SC, Co-STOP will increase smoking treatment use (i.e., use of NRT + counseling) and the likelihood of making a quit attempt.
研究类型
注册 (估计的)
阶段
- 第四阶段
联系人和位置
学习联系方式
- 姓名:Jessica M Cook, PhD
- 电话号码:(608) 256-1901
- 邮箱:Jessica.Cook2@va.gov
研究联系人备份
- 姓名:Jennifer M Betts, PhD
- 电话号码:(608) 280-7084
- 邮箱:jennifer.betts@va.gov
学习地点
-
-
Wisconsin
-
Madison、Wisconsin、美国、53705-2254
- William S. Middleton Memorial Veterans Hospital, Madison, WI
-
接触:
- Elana G Brubaker, MSW BS
- 电话号码:17854 (608) 256-1901
- 邮箱:elana.brubaker@va.gov
-
首席研究员:
- Jennifer M. Betts, PhD
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Smoke at least one cigarette per day
- Be engaged in VA outpatient substance use treatment for at least one month
- Be medically eligible to use Nicotine Replacement Therapy (NRT)
- Not currently receiving smoking treatment
- Not currently at high risk for suicide
- Have an email address
Exclusion Criteria:
- Unable to give informed, voluntary consent to participate
- Incarceration
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Co-STOP
Co-STOP participants will receive evidence-based smoking treatment, that does not require a commitment to quit, as routine part of their SUD care unless they decline treatment.
This will include 4 months of counseling and NRT to support the smoking change goal on which they would like to work.
All participants in the Co-STOP condition will receive Healthy Changes treatment, which focuses on making manageable changes to smoking, unless they choose to make a quit attempt (or decline treatment).
If they choose to make a quit attempt, they will receive Cessation Treatment.
|
All participants in Co-STOP will receive their choice of nicotine mini-lozenge or gum for 4 months, unless they decline or start Cessation Treatment instead.
If <30 min to first cigarette of the day then 4mg mini-lozenges/gum will be prescribed, and if ≥30 min to first cigarette of the day then 2-mg mini-lozenges/gum will be prescribed.
Participants will be encouraged to use NRT in place of smoking (5-15 pieces/day).
其他名称:
If a participant enters Cessation Treatment, they will receive combination NRT (patch with participant choice of mini-lozenge or gum).
Nicotine patch dosing, which will begin on the TQD, will be will be consistent with medication labeling; i.e., if smoking >10 cigarettes/day= starting at 21-mg; if smoking ≤10 cigarettes/day = starting at 14-mg nicotine patches.
Similarly, dosing for nicotine mini-lozenge/gum: <30 min to 1st cig/day starting at 4mg every 1-2 hours; if ≥30 min to 1st cig/day, then starting at 2mg every 1-2 hours.
其他名称:
All participants who enter cessation treatment will receive five, 15-20 minute counseling calls over 16 weeks.
Calls will be scheduled at approximately 1-week pre-target quit day (TQD), 1-day post TQD, and three flexible sessions up to week 16.
Prior to quitting, the study counselor will reinforce reasons for quitting, discuss past quit experiences, and develop a quit day plan.
Post-quit sessions will include coping with cravings, identifying high-risk situations (e.g., co-use with other substances), developing behavioral plans for high-risk situations, and a plan to manage a lapse/relapse.
All participants in Co-STOP will receive counseling calls for Healthy Changes Counseling unless they choose to enter Cessation Treatment or decline.
Participants will receive five, 15-20 minute counseling phone calls over 16 weeks.
During counseling calls, the study counselor will work with participants to develop smoking change goals, including smoking reduction, changing smoking contexts, and using NRT.
Counseling sessions will explore participants' motivations for changing their tobacco use and address pragmatic issues such as co-use with other substances, work contexts, smoking policies, and habits that interfere with desired changes.
Counseling will emphasize competence and self-efficacy, both of which will be linked to the practice of smoking change skills.
|
|
有源比较器:Standard Care
Participants in Standard Care will be asked if they are interested in quitting smoking in the next month, and if so, they will be offered Cessation Treatment, which is consistent with existing VA standard care.
|
If a participant enters Cessation Treatment, they will receive combination NRT (patch with participant choice of mini-lozenge or gum).
Nicotine patch dosing, which will begin on the TQD, will be will be consistent with medication labeling; i.e., if smoking >10 cigarettes/day= starting at 21-mg; if smoking ≤10 cigarettes/day = starting at 14-mg nicotine patches.
Similarly, dosing for nicotine mini-lozenge/gum: <30 min to 1st cig/day starting at 4mg every 1-2 hours; if ≥30 min to 1st cig/day, then starting at 2mg every 1-2 hours.
其他名称:
All participants who enter cessation treatment will receive five, 15-20 minute counseling calls over 16 weeks.
Calls will be scheduled at approximately 1-week pre-target quit day (TQD), 1-day post TQD, and three flexible sessions up to week 16.
Prior to quitting, the study counselor will reinforce reasons for quitting, discuss past quit experiences, and develop a quit day plan.
Post-quit sessions will include coping with cravings, identifying high-risk situations (e.g., co-use with other substances), developing behavioral plans for high-risk situations, and a plan to manage a lapse/relapse.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Treatment Engagement
大体时间:At the end of 4 month treatment
|
Rates of self-reported use of nicotine replacement therapy and attending at least one counseling session
|
At the end of 4 month treatment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
24h Quit Attempt
大体时间:At the end of 4 month treatment
|
Rates of self-reported quit attempt lasting at least 24 hours during the study
|
At the end of 4 month treatment
|
合作者和调查者
调查人员
- 首席研究员:Jennifer M. Betts, PhD、William S. Middleton Memorial Veterans Hospital, Madison, WI
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- NURA-001-25F
- 1IK2RD001577 (其他赠款/资助编号:Department of Veterans Affairs)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.